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ABSTRACT 90 
Background: Asthma is a heterogeneous disease in which age-of-onset plays an important 91 
role. 92 
Objective: We sought to identify the genetic variants associated with time-to-asthma onset. 93 
Methods: We conducted a large-scale meta-analysis of nine genome-wide association studies 94 
of time-to-asthma onset (total of 5,462 asthmatics with a broad range of age-of-asthma onset 95 
and 8,424 controls of European ancestry) performed using survival analysis techniques. 96 
Results: We detected five regions associated with time-to-asthma onset at genome-wide 97 
significant level (P<5x10-8). We evidenced a new locus in 16q12 region (near cylindromatosis 98 
turban tumor syndrome gene (CYLD)) and confirmed four asthma risk regions: 2q12 99 
(IL1RL1), 6p21 (HLA-DQA1), 9p24 (IL33) and 17q12-q21 (ZPBP2-GSDMA). Conditional 100 
analyses identified two distinct signals at 9p24 (both upstream of IL33) and at 17q12-q21 101 
(near ZPBP2 and within GSDMA). These seven distinct loci explained together 6.0% of the 102 
variance in time-to-asthma onset. In addition, we showed that genetic variants at 9p24 and 103 
17q12-q21 were strongly associated with an earlier onset of childhood asthma (P≤0.002) 104 
whereas 16q12 SNP was associated with a later asthma onset (P=0.04). A high burden of 105 
disease risk alleles at these loci was associated with earlier age-of-asthma onset (4 years 106 
versus 9-12 years, P=10-4). 107 
Conclusion: The new susceptibility region for time-to-asthma onset at 16q12 harbors variants 108 
that correlate with the expression of CYLD and NOD2 (nucleotide-binding oligomerization 109 
domain 2), two strong candidates for asthma. This study demonstrates that incorporating the 110 
variability of age-of-asthma onset in asthma modeling is a helpful approach in the search for 111 
disease susceptibility genes. 112 
 113 
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Key Messages:  115 
• 16q12 genetic variants are associated with time-to-asthma onset and correlate with 116 
CYLD and NOD2 expressions. 117 
• Genetic variants at 9p24 (upstream of IL33) and 17q12-q21 (nearby ZPBP2 and within 118 
GSDMA) are associated with an earlier asthma-onset whereas variants at 16q12 are 119 
associated with a later asthma onset. 120 
• Taking into account the variability of age-of-asthma onset in disease modeling can 121 
increase the power of identifying new genes involved in asthma physiopathology. 122 
 123 
Capsule summary:  124 
This large-scale meta-analysis of nine genome-wide association studies identified 16q12 125 
genetic variants associated with time-to-asthma onset that correlate with CYLD and NOD2 126 
expressions, two strong candidate genes implicated in inflammation.  127 
 128 
Keywords: Asthma, age-of-onset, genetics, genome-wide association study, survival analysis, 129 
conditional analysis, CYLD, NOD2 130 
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Abbreviations: 132 
CYLD: Cylindromatosis (turban tumor syndrome) 133 
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GSDMA: Gasdermin A 135 
GWAS: Genome-wide association study 136 
HLA-DQA1: Major histocompatibility complex, class II, DQ alpha 1 137 
HR: Hazard ratio 138 
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IL33: Interleukin 33 140 
LCL: Lymphoblastoid cell line 141 
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QC: Quality control 145 
SNP: Single nucleotide polymorphism 146 
TAO: time-to-asthma onset 147 
ZPBP2: Zona pellucida binding protein 2 148 
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INTRODUCTION 150 
The prevalence of asthma has dramatically increased over the past decades in high-income 151 
countries, affecting 5–16% of people worldwide.1 It is the most common chronic disease 152 
among children and a decrease in the age-of-asthma onset has been recently documented.2  153 
Asthma is a complex and heterogeneous disease with variable clinical expression over the life 154 
span.1 It is now well recognized that asthma is not a single disease but rather a collection of 155 
different phenotypes which may represent different manifestations of a common underlying 156 
pathological process or may be separate disease entities.3 One of the simplest characteristic 157 
that can be used to differentiate disease phenotypes is the age at onset.4,5 Indeed, asthma 158 
displays different characteristics according to the lifetime period at which it occurs.6 Early age 159 
of onset is more frequently associated with a family history of asthma, allergy sensitization 160 
and clinical response to triggers, whereas late-onset disease is associated with eosinophilic 161 
inflammation and obesity, is more common in women, and is generally less allergic.3 162 
The risk of developing asthma has a strong genetic component, with estimated heritability 163 
ranging from 35 to 95%.7 Genome-wide association studies (GWASs) have been successful in 164 
identifying more than 20 loci associated with asthma.8 However, the genetic factors identified 165 
to date account only for a small part of the genetic component of the disease.1 This hidden 166 
heritability might be linked to the phenotypic heterogeneity of asthma.9 The vast majority of 167 
GWASs conducted until now have analyzed asthma as a binary phenotype. A few genetic 168 
studies have considered more specific definition of asthma incorporating the age of disease 169 
onset. A genome-wide linkage screen conducted for time-to-asthma onset in French families 170 
revealed two regions, 1p31 and 5q13, potentially linked to this phenotype.10 A single GWAS 171 
has been performed on age-of-asthma onset in asthmatic children and led to the identification 172 
of two loci, not found by the previous asthma GWASs; these loci on chromosomes 3p26 and 173 
11q24 were associated with an earlier onset of childhood asthma.11 Moreover, the effect of 174 
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17q12-q21 genetic variants, identified by the first GWAS of asthma,12 was found to be 175 
restricted to early-onset asthma.13,14 176 
Instead of stratifying the data according to age-of-onset of disease using an arbitrary 177 
threshold, one can integrate the age-of-onset in modeling asthma risk, by using survival 178 
analysis methodology applied to both asthmatic and non-asthmatic subjects. The goal of the 179 
present study was to identify the genetic determinants underlying time-to-asthma onset in a 180 
large meta-analysis of 5,462 asthmatics and 8,424 controls from nine independent European-181 
ancestry populations. 182 
 183 
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METHODS 184 
Populations 185 
We studied 13,886 individuals of European ancestry from nine independent studies (one birth 186 
cohort, five population-based and three family studies) which were part of the GABRIEL 187 
European consortium on the genetics of asthma.14 A brief description of these studies with 188 
appropriate references is provided in the online repository and in Table E1. All of these 189 
studies had the age of asthma onset and imputed genetic data available. 190 
For all studies, ethical approval was obtained from the appropriate institutional ethic 191 
committees and all individuals or child's legal guardians provided written informed consent. 192 
 193 
Time-to-asthma onset definition 194 
Definition of asthma was based on report of doctor’s diagnosis and/or on standardized 195 
questionnaires (see online repository). To model time-to-asthma onset (TAO), we used age of 196 
onset or age at first wheeze for individuals who developed asthma, while in individuals who 197 
were free of disease upon examinations, we used age at last examination. 198 
 199 
Genotyping 200 
Genotyping, single nucleotide polymorphism (SNP) imputation process and quality control 201 
(QC) criteria (for individuals and SNPs) for each study are described in Table E1 in the online 202 
repository. All datasets were genotyped at Centre National de Génotypage (CNG, Evry, 203 
France), as part of the European GABRIEL asthma consortium.14 Quality control and 204 
imputations were performed independently for each study. Genome-wide imputations were 205 
conducted using MACH 1.0 software,15 with reference haplotype panels from HapMap 2. 206 
SNPs with imputation quality score (Rsq) ≥ 0.5 and minor allele frequency ≥ 1% were kept 207 
for analysis. Then, to further investigate the regions associated with time-to-asthma onset at 208 
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the genome-wide significant level, we used imputed data from the 1000 Genomes Project and 209 
applied the same SNP QC criteria. 210 
 211 
Statistical analysis and strategy of analysis 212 
After the study-specific QC, a total of 13,886 individuals from the nine cohorts were included 213 
in the present study. In each dataset, association between time-to-asthma onset and individual 214 
SNPs was investigated under an additive genetic model using a Cox proportional-hazards 215 
regression model adjusted for sex and the first four principal components to account for 216 
population structure. A robust sandwich estimation of the variance16 was used in family data 217 
to take into account familial dependencies. Moreover, due to the complex sampling design of 218 
the GABRIELA study, survey regression techniques were used for this study to estimate 219 
robust standard errors (‘svy’ command in Stata). Proportional hazard assumptions for the 220 
main SNP effect were tested and never rejected. Genome-wide association studies of time-to-221 
asthma onset were first conducted in each of the nine datasets separately, and then combined 222 
through meta-analysis in order to increase power and to obtain more robust findings. Meta-223 
analyzed hazard-ratios (HRs) and 95% confidence intervals (CIs) were calculated using a 224 
fixed-effect (inverse variance) model. To assess heterogeneity of SNP effect across studies, 225 
the Cochran’s Q statistic was calculated. If heterogeneity was evidenced, a random-effect 226 
model was fitted. All analyses were performed using Stata® version 13.1 (STATA Corp., 227 
College Station, Texas, USA). After the meta-analysis, we only kept SNPs for which at least 228 
66% of the studies (≥6 studies among the 9 studies) participated to the summary statistics in 229 
the meta-analysis, to reduce the rate of false-positive findings. The meta-analysis results were 230 
obtained for a total of 2,387,926 SNPs. We used the classical threshold of P-value≤5x10-8 to 231 
declare a meta-analyzed SNP effect as genome-wide significant.  232 
 233 
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Conditional analysis to uncover distinct signals at TAO-associated loci 234 
To identify distinct TAO-associated SNPs in each region harboring genome-wide significant 235 
signals, we re-analyzed separately these regions in each of the nine studies. For that purpose, 236 
we added the region top SNP into the primary Cox model as a covariate and tested the effect 237 
of each other SNP of that region. Then, the results were meta-analyzed using the same 238 
strategy as the primary GWASs. If a secondary signal was detected in a region, a second run 239 
of conditional analyses was performed to check for a third distinct signal in that region. 240 
Length of explored regions was based on regional association plots and ranged from 200 kb to 241 
500 kb depending on recombination hotspots. 242 
 243 
eQTL analysis and functional annotations 244 
We queried whether significant SNPs (or their proxies) associated with time-to-asthma onset 245 
at P≤5x10-8 and potentially secondary signals from conditional analysis were expression 246 
quantitative trait loci (eQTLs). We used existing eQTL databases in multiple tissues 247 
(especially blood and lung) for populations of European ancestry (see online repository).17-23 248 
Functional annotations of significant SNPs (or their proxies) were obtained using 249 
ENcyclopedia Of DNA Elements (ENCODE) data24 provided by the HaploReg tool.25 250 
 251 
Relationship of TAO-associated loci with age-of-asthma onset 252 
In a first step, we investigated in asthmatics whether each of the SNPs associated with TAO 253 
were also associated with age-of-asthma onset using a non-parametric rank test followed by a 254 
non-parametric equality-of-medians test. In a second step, we assessed the cumulative effect 255 
of risk alleles of SNPs found associated with the age-of-asthma onset at step 1. For that 256 
purpose, we used either the number of risk alleles or the quintiles of a polygenic score 257 
distribution. The polygenic risk score is the weighted sum of the number of age of asthma 258 
13 
onset associated alleles with weight being the log of adjusted hazard ratio estimated in 259 
asthmatics only. The associations were tested in eight studies for which we had access to raw 260 
data (all datasets except ALSPAC) using a cox proportional hazard model adjusted on sex and 261 
principal components. 262 
 263 
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RESULTS 264 
Description of populations 265 
A total of 13,886 subjects were included in the present study (5,462 asthmatics and 8,424 266 
non-asthmatics). Asthmatics had a mean age-of-asthma onset of 12.5 years (ranging from 0.5 267 
to 75 years, Figure E1), a mean age of 26.8 years at examination (mean per study ranging 268 
from 9.1 to 51.3 years) and 52.6% were males. Non-asthmatics had a mean age of 32.4 years 269 
at examination (mean per study ranging from 8.9 to 55.8 years) and 49% were males (Table 270 
E1). 271 
 272 
Genetic variants associated with time-to-asthma onset  273 
The Manhattan and the Q-Q plots of the meta-analysis of time-to-asthma onset GWAS results 274 
are shown in Figure 1 and Figure E2 in the online repository respectively. A total of 155 275 
SNPs were associated with time-to-asthma onset at the genome-wide significance level of 276 
P<5x10-8. These SNPs clustered into five distinct chromosomal regions (Table I), that 277 
included a new risk locus on 16q12 (nearby CYLD (cylindromatosis turban tumor syndrome), 278 
1 SNP) and four established risk loci for asthma: 2q12 (IL1RL1-IL18R1, 7 SNPs), 6p21 279 
(nearby HLA-DQA1, 1 SNP), 9p24 (flanking IL33, 25 SNPs) and 17q12-q21 (121 SNPs 280 
spanning 389 kb, and with the main signal located near ZPBP2). The regional association 281 
plots for these genome-wide associated loci are shown in Figures 2 and E3, and the forest 282 
plots for the top signal in each region are shown in Figure E4. Three additional loci were 283 
associated with time-to-asthma onset at a suggestive significance threshold (5x10-8<P<10-6; 284 
Table I): MAP4K4 (2q11-q12), RORA (15q22) and IL4R (16p12-p11).  285 
To determine whether any of the five TAO loci harbored additional association signals, we 286 
performed conditional association analysis in each region. For this analysis, a threshold of 287 
P≤2.1x10-5 was used to declare significance, corresponding to a Bonferroni threshold for 288 
15 
2,382 independent tests. These analyses evidenced two secondary signals (Table II and Figure 289 
E5 in the online repository): 1) rs413382  in 9p24 region at 73 kb of IL33 (P=9.7x10-6 after 290 
conditioning on top SNP and P=5.9x10-8 in the primary meta-analysis) and 2) rs3859192  in 291 
17q12-q21 region within GSDMA (P=4.0x10-6 after conditioning on top SNP and P=1.5x10-13 292 
in the primary meta-analysis). In contrast, at 2q12, 6p21 and 16q12 regions, the inclusion of 293 
the most significant time-to-asthma onset GWAS SNP as a covariate in association analysis 294 
resulted in nearly complete reduction of the association signal in these regions, suggesting 295 
that there was no evidence for a second distinct genetic factor in these regions.  296 
To obtain a denser map of the new TAO 16q12 locus, we repeated association analyses using 297 
1000 Genomes Project imputed SNPs. These analyses strengthened our original finding with 298 
additional signals (3.8x10-8≤P≤2.6x10-7) located in an intergenic region encompassing the 299 
lead SNP rs1861760 (Table E2 and Figure E6). These SNPs were in moderate to high LD 300 
with rs1861760 (0.71≤r²≤0.81) and thus did not represent independent signals from that top 301 
hit. Similar analyses conducted in the four other TAO-associated regions also supported our 302 
original findings and did not evidence any additional independent signal in these regions.  303 
Overall, the seven distinct SNPs (five top SNPs and two secondary SNPs) associated with 304 
TAO showed low heterogeneity between studies (P>0.11) and explained together 6.0% of the 305 
variance in time-to-asthma onset. 306 
 307 
Functional annotations and effect on gene expression 308 
To provide some insights into the potential molecular mechanisms underlying the TAO-309 
associated variants, we queried whether the five top SNPs and two secondary signals (and 310 
their proxies) were 1) tagging potentially deleterious SNPs, 2) located in regulatory elements, 311 
and 3) reported to influence the expression of one or more of nearby genes (eQTLs at 312 
P<5x10−5). We focused on the new TAO risk locus at 16q12 region. Functional annotations 313 
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for the remaining six loci are presented in the online repository and eQTL data are presented 314 
in Table III (main results) and in Table E3 in the online repository. 315 
The 16q12 TAO-associated variants are located in an intergenic region delimited by two 316 
recombination hotspots on each side, near CYLD (22 kb downstream). The rs1861760 maps to 317 
FOXJ1 and SOX binding sites. This SNP and/or its proxies correlate with the expression of 318 
CYLD in both blood and human lung tissues and of NOD2 (nucleotide-binding 319 
oligomerization domain 2) in blood20 (Table III for main results and Table E3 in the online 320 
repository).17,20 321 
 322 
Relationship between TAO-associated variants and age-of-asthma onset 323 
To investigate whether TAO-associated SNPs influence the age-of-asthma onset, we 324 
compared, in asthmatics, the distribution of age-of-asthma onset according to the number of 325 
risk alleles at each of the seven main and secondary TAO-associated SNPs (Figure 3). 326 
Asthmatic subjects carrying one or two copies of risk allele at 17q12-q21 SNPs (rs9901146 327 
and rs3859192) or at 9p24 rs928413 had a younger age-of-asthma onset than non-carriers 328 
(median 6-8 years versus 10 years (P≤6x10-4) and median 6-8 years versus 9 years (P=0.002), 329 
respectively), whereas those having at least one copy of rs1861760 risk-allele at 16q12 had a 330 
later age-of-asthma onset than non-carriers (median 10 years versus 8 years; P=0.04). No 331 
significant difference was found for the other three SNPs. We evidenced that an increased 332 
number of risk alleles at these four SNPs was associated with a younger age-of-asthma onset 333 
(median 12 years for carrying one risk allele to 4 years for carrying 6-8 risk alleles; P=10-4). 334 
Finally, we detected a strong association between the age-of-asthma onset and the polygenic 335 
risk score (from median 10 years in first quintile to 6 years in last quintile; P=4x10-4). 336 
 337 
Comparison of time-to-asthma onset GWAS results with previous asthma GWASs 338 
17 
To investigate the impact of taking into account the age-of-asthma onset in disease modeling 339 
through survival analysis, we explored whether the top TAO SNPs were associated with 340 
asthma modeled as a binary trait in the nine cohorts included in the present study (Table E4, 341 
see online repository). We also investigated GABRIEL top SNPs in TAO meta-analysis 342 
(Table E4).14 We observed a strong decrease of heterogeneity of SNP effect across studies in 343 
TAO analysis (PHet≥0.11) compared with asthma binary trait analyzed in the same datasets 344 
(PHet≥0.004) as well as in all GABRIEL datasets (PHet≥0.0009), especially in 9p24 and 17q12-345 
q21 regions. The association signals were always more significant in TAO analysis as 346 
compared with the binary trait analysis in the same datasets. This increase of significance 347 
level was very high: 100-fold for 2q12 and 16q12, and 104 to 106-fold for 9p24 and 17q12-348 
q21. In fact, the asthma binary trait analysis only detected two loci (HLA and GSDMA) at the 349 
genome-wide significance level out of the seven TAO-associated loci. Conversely, the present 350 
TAO analysis identified at the genome-wide significance level four of the six main published 351 
GABRIEL regions,14 and event at higher significance for 9p24 and 17q12-q21 regions (100 to 352 
104-fold) as compared to GABRIEL significance levels. The two remaining GABRIEL loci 353 
not detected by our TAO analysis were those with the weaker effects (OR=1.12 for rs744910 354 
in 15q22 and rs2284033 in 22q13) in GABRIEL meta-analysis.14 355 
Finally, we evaluated whether previously reported susceptibility loci for asthma26 were 356 
associated with time-to-asthma onset in our meta-analysis (see online repository, Table E5). 357 
Among the 21 loci detected in European populations, 12 were replicated at 5% in our TAO 358 
meta-analysis with the same direction of effects. Among the nine non-replicated signals, three 359 
SNPs (or some proxies) were not available in our data, and the remaining six loci had been 360 
reported for specific phenotypes: asthma exacerbation, age-of-asthma onset per se in 361 
asthmatic children only (quantitative trait) or childhood asthma (binary trait).11,27,28 362 
 363 
18 
DISCUSSION 364 
By taking into account the age-of-asthma onset in asthma association analysis, we identified 365 
in this large meta-analysis including both asthmatic and non-asthmatic individuals, adults and 366 
children, a new susceptibility locus at 16q12 associated with time-to-asthma onset and 367 
confirmed the involvement of six other distinct loci belonging to four regions in asthma 368 
pathogenesis (2q12, 6p21, 9p24 and 17q12-q21). Genetic variants at 9p24 and 17q12-q21 369 
were strongly associated with an earlier onset of childhood asthma whereas the 16q12 lead 370 
SNP was associated with a risk of later onset asthma. 371 
The most significant 16q12 genetic variant (rs1861760) is located nearby CYLD and NOD2 372 
and also maps to a binding site of FOXJ1, a transcription factor associated with allergic 373 
rhinitis.29 Genetic variants located in a 130-kb region around rs1861760 were reported 374 
associated with immune-related diseases: inflammatory bowel diseases (Crohn’s disease) and 375 
leprosy.30-35 Interestingly, haplotype reconstruction (Figure 4) showed that the TAO 376 
rs1861760-A risk allele was always associated with SNP alleles that conferred a decreased 377 
risk of Crohn’s disease (rs17221417-C, rs5743289-C and rs2076756-A located in NOD2 and 378 
rs12324931-A located in CYLD)30-32,35,36 and of leprosy (rs16948876-G located in intergenic 379 
region at 2 kb from rs1861760).33 Indeed, GWASs revealed common genetic susceptibility 380 
loci for asthma and other immune-related disorders, suggesting shared molecular pathways 381 
involved in their etiology; however opposite alleles appear to be at risk.37 Interestingly, an 382 
opposite effect of rs1861760-A allele is also observed at the gene expression level. Thus, 383 
TAO risk-allele at rs1861760 correlated with both the expression of CYLD and NOD2 in 384 
blood but with an opposite effect.20 However, this TAO risk allele was only associated with 385 
increased CYLD expression in lung tissue.17 CYLD encodes a deubiquitinating enzyme that 386 
regulates diverse physiological processes including immune response and inflammation.38 387 
CYLD mainly acts as a negative regulator of nuclear factor-κB (NFkB1) to protect the host 388 
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from an over-reactive inflammatory response.38 Conversely NOD2, which plays an important 389 
role in the innate immune response to intracellular bacterial lipopolysaccharides (LPS), 390 
activates the NFkB1 pathway.39 NFkB1 is a pleiotropic transcription factor that acts as a key 391 
regulator of immune and inflammatory genes, and activation of the NFkB1 pathway has been 392 
implicated in airway inflammation and asthma.40,41 Moreover, FOXJ1 transcription factor that 393 
binds to the genomic region encompassing 16q12 TAO-associated SNP (rs1861760) was 394 
described to inhibit NFkB1 activity.42 Recently, CYLD has been shown to regulate lung 395 
fibrosis in mice by inhibiting transforming growth factor-β-signaling (TGF-β) through a 396 
decrease of SMAD3 protein stability.43 Of interest, SMAD3 has been reported to be associated 397 
with asthma by previous GWAS.14 398 
Defining the phenotype is an important consideration because phenotypic heterogeneity can 399 
reduce power of GWAS.44 In the present analyses, we studied the variability of time-to-400 
asthma onset in both asthmatics and non-asthmatics based on survival analysis methods. The 401 
information used for such analysis was the age-of-onset in asthmatics and the age at last 402 
examination or death in non-asthmatics. In such a model, unaffected subjects represent 403 
censored observations as they are still at risk for disease, being perhaps too young to exhibit 404 
the trait. This approach, which allowed combining the age-of-asthma onset together with the 405 
disease status (affected/unaffected) led to decrease the genetic heterogeneity across studies 406 
and increase the power to detect association signals (upon 106-fold increase as compared to 407 
the disease status only analysis. More specifically, increased evidence of association was 408 
observed in regions where age-of-asthma onset explained at least in part the genetic 409 
heterogeneity such as the 17q12-q21 locus for which a restricted SNP effect to a particular 410 
group of age-of-onset (early childhood onset asthma) was demonstrated.13 Moreover, this 411 
analysis led to the identification of a new locus at 16q12 near CYLD and of an additional 412 
signal in the 9p24 region. These results support the hypothesis that a better consideration of 413 
20 
the phenotypic heterogeneity of asthma may help to disentangle the genetic heterogeneity of 414 
asthma.  415 
Our study included both children and adult asthmatic subjects. Age-of-disease onset may be 416 
subject to recall bias, especially among individuals who are the furthest from the time of the 417 
first symptoms (e.g. adults who suffered of asthma in childhood) because it is often defined in 418 
a retrospective manner. However, high accuracy of the self-reported year of asthma onset by 419 
adult subjects has been shown by two independent studies among which the European 420 
Community Respiratory Health Survey, which was part of the present study.45,46 Erroneous 421 
recall of the age-of-asthma onset is unlikely to have significantly affected the results since we 422 
observed little genetic heterogeneity across studies (e.g. childhood onset asthma reported by 423 
either adults or children). 424 
It was suggested that some genetic variants might influence asthma in an age-specific manner. 425 
Among TAO-associated SNPs, we confirmed the association of 17q12-q21 SNPs with an 426 
early age-of-asthma onset13,14 and evidenced for the first time that the top 9p24 genetic variant 427 
near IL33 was also associated with early childhood-onset asthma (median age-of-onset of 6-8 428 
years in risk-allele carriers). Indeed, in GABRIEL meta-analysis, 9p24 SNPs were more 429 
strongly associated with early-onset asthma (before 16 years) than late-onset asthma (after 16 430 
years), but this difference was not significant.14 Conversely, genetic variants at the new 431 
susceptibility locus, 16q12, conferred a risk of later onset asthma (median age-of-onset of 10 432 
years in risk-allele carriers). Moreover, we evidenced that a high burden of disease risk alleles 433 
at these loci is associated with earlier age-of-asthma onset (4 years versus 9-12 years). This 434 
difference in asthma onset may reflect difference in patterns of onset of disease.47 Indeed, we 435 
evidenced in the GABRIELA study that persistent early wheezing subjects carried more risk 436 
alleles than transient early wheezing subjects, and we confirmed previous association between 437 
persistent early wheezing and 9p24 and 17q12-q21 loci (data not shown). The 17q12-q21 438 
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genetic variants were reported associated with persistent childhood wheeze phenotype 439 
whereas 9p24 were mostly associated with intermediate onset wheeze but also with persistent 440 
early wheeze.48,49 Moreover, 17q12-q21 SNPs were associated with fractional exhaled Nitric 441 
Oxide (FeNO) levels in children but not in adults, childhood severe asthma and allergic 442 
rhinitis, and 9p24 SNPs were associated with childhood severe asthma, asthma-plus-rhinitis, 443 
atopic asthma, allergy and eosinophil counts.50-55 444 
In summary, we identified five regions harboring seven distinct signals that were associated 445 
with time-to-asthma onset, among which the 16q12 region that is reported for the first time. 446 
Several lines of evidence suggest that CYLD and NOD2 located in that region are strong 447 
candidate genes for asthma. This study demonstrates that incorporating the variability of age-448 
of-asthma onset in disease modeling is a useful strategy to uncover new disease genes. 449 
 450 
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Table I. Top SNPs in main loci associated with time-to-asthma onset at genome-wide (P≤5x10-8) and suggestive significance levels (5x10-659 
8<P<10-6) 660 
      Time to asthma onset - N=13,886 
Chromosome Marker Position* 
Nearest gene(s) 
(kb distance) 
Effect/ 
Ref Alleles† 
Effect 
Freq 
Hazard Ratio 
[95% CI] 
P‡ P-Het** 
Loci with genome-wide significance - P≤5x10-8  
2q12 rs10208293 102966310 IL1RL1*** G/A 0.73 1.14 [1.08-1.19] 3.1x10-8 0.26 
6p21 rs9272346 32604372 HLA-DQA1 (0.8) A/G 0.59 1.13 [1.08-1.17] 1.6x10-8 0.12 
9p24 rs928413 6213387 IL33 (2) G/A 0.25 1.19 [1.13-1.25] 6.5x10-16 0.15 
16q12 rs1861760 50857693 CYLD (22) A/C 0.04 1.28 [1.17-1.40] 4.2x10-8 0.11 
17q12-q21 rs9901146 38043343 ZPBP2 (9) 
GSDMB (17) 
G/A 0.51 1.18 [1.13-1.22] 1.9x10-16 0.17 
  
Suggestive loci - 5x10-8<P<10-6  
2q11-q12 rs12468899 102426140 MAP4K4*** G/A 0.69 1.12 [1.09-1.16] 1.7x10-7 0.89 
15q22 rs11071559 61069988 RORA*** C/T 0.85 1.16 [1.10-1.24] 8.3x10-7 0.96 
16p12-p11 rs1805013 27373980 IL4R*** T/C 0.05 1.22 [1.13-1.32] 8.0x10-7 0.37 
*Position in base pairs (bp) – build 37.3 NCBI 661 
 33 
†For the calculation of the hazard ratios, effect alleles were designated as risk alleles. Effect Freq denotes frequency of the effect allele, CI 662 
confidence interval, and Ref reference allele. 663 
‡P-value obtained from single-SNP Cox model for time-to-asthma onset adjusted for sex and principal components (fixed-effect model when 664 
there was no significant evidence of heterogeneity or random-effect model otherwise) 665 
**P-Het reflects P-value of Cochran’s Q statistic across studies 666 
***SNP is located within reported gene 667 
668 
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Table II. Secondary signals associated with time-to-asthma onset after stepwise conditional analysis in 9p24 and 17q12-q21 regions. This table 669 
contains, for these two regions, the top time-to-asthma onset SNP in bold (rs928413 and rs9901146 respectively) and the most significant SNP in 670 
the conditional analysis, after fitting the lead SNP in the region. 671 
      Single SNP analysis Fitted SNP(s) 
Chr Marker Nearest gene 
(kb distance) 
Position* Effect/Ref 
Alleles† 
Effect 
Freq 
Hazard Ratio 
[95% CI] 
P‡ P-Het** Hazard Ratio 
[95% CI] 
P‡ P-Het** 
9p24 region        rs928413 
9 rs413382 IL33 (73) 6142948 A/C 0.80 1.15 
[1.08-1.22] 
5.9x10-8 0.84 1.13 
[1.06-1.20] 
9.7x10-6 0.80 
9 rs928413 IL33 (2) 6213387 G/A 0.25 1.19 
[1.13-1.25] 
6.5x10-16 0.15 - - - 
17q12-q21 region        rs9901146 
17 rs9901146 ZPBP2 (9) 38043343 G/A 0.51 1.18 
[1.13-1.22] 
1.9x10-16 0.17 - - - 
17 rs3859192 GSDMA*** 38128648 T/C 0.48 1.16 
[1.12-1.21] 
1.5x10-13 0.90 1.11 
[1.06-1.15] 
4.0x10-6 0.74 
*Position: Position in base pairs (bp) - build 37.3 NCBI 672 
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†For the calculation of the hazard ratio, effect alleles were designated as risk alleles. Effect Freq denotes frequency of the effect allele, CI 673 
confidence interval, and Ref reference allele 674 
‡P-values are obtained from Cox model of time-to-asthma onset adjusted for sex and principal components  675 
**P-Het reflects P-value of Cochran’s Q statistic across studies 676 
***SNP is located within reported gene 677 
  678 
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Table III. Main cis-eQTLs results for the top SNPs in genome-wide associated regions from the meta-analysis of time-to-asthma onset. We 679 
focused on eQTLs measured in blood, lymphoblastoïd cell lines (LCLs) and lung tissue. 680 
Locus SNP* 
(LD with top SNP) 
Alleles 
(Ref/Effect) 
Gene(s) Range of P-values Tissue Source†† 
2q12 rs10208293 G/A IL18RAP, IL18R1 2.5x10-13-9.8x10-198 Blood, LCLs Blood eQTLs, eQTL Browser 
6p21 rs9272346 G/A HLA-DQA1/DQA2/DQAS1/ 
DQB1/DQB2,HLA-DRA/DRB1/ 
DRB5/DRB6, TAP2 
1.3x10-6-2.1x10-121 LCLs, Lung, Blood eQTL_Chicago,GTEx, Blood 
eQTLs 
16q12 rs1861760 C/A NOD2 3.6x10-11 Blood Blood eQTLs 
rs5743266† 
(D'=1, r²=0.02) 
 CYLD, NOD2 5.0x10-9-3.2x10-120 Blood Blood eQTLs 
rs7205760† 
(D'=1, r²=0.005) 
 CYLD, NOD2 2.8x10-6-4.0x10-15 Lung, Blood Lung eQTLs, Blood eQTLs 
17q12-q21 rs9901146 A/G GSDMB, ORMDL3 3.8x10-6-9.8x10-198 Blood, LCLs Blood eQTLs, GTEx, eQTL 
Browser, eQTL_Chicago 
rs3859192 C/T GSDMA, GSDMB, ORMDL3 1.1x10-7-2.5x10-12 Lung, LCLs GTEx, eQTL Browser 
* Top genome-wide significant SNPs in time-to-asthma onset meta-analysis and secondary associations identified by conditional analyses are 681 
indicated in bold. 682 
 37 
†Haplotype reconstruction was done using Haploview; the effect allele of the top SNP (A-rs1861760) is always transmitted with the effect allele 683 
of its proxy (G-rs5743266 and G-rs7205760). 684 
††Interrogated databases: eQTL Browser (LCLs of British subjects with asthma or eczema),18 Blood eQTL Browser (non-transformed peripheral 685 
blood sample),20 Lung eQTLs (lung),17GTEx eQTL Browser v4 (several tissues among which blood and lung),23 and eQTL Chicago Browser 686 
(LCLs).19,21,22  687 
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FIGURE LEGENDS 688 
Figure 1. Manhattan plot showing the association P-values of the genome-wide association 689 
results for time-to-asthma onset from the meta-analysis. The –log10 of the P-value for each of 690 
2,400,368 SNPs (y-axis) is plotted against the genomic position (x-axis). The solid red line 691 
indicates the genome-wide significance threshold of P=5x10-8. 692 
Figure 2. Regional association plot of the 16q12 region using Locuzoom software.56 SNPs are 693 
plotted with their P-values (-log10 values, left y-axis) as a function of genomic position (x-694 
axis). Estimated recombination rates (right y-axis) taken from 1000G (EUR) are plotted to 695 
reflect the local LD structure around the top associated SNP (purple circle) and correlated 696 
proxies (according to a blue to red scale from r²=0 to 1). 697 
Figure 3. Relationship between time-to-asthma onset associated SNPs and age-of-asthma 698 
onset. Part A) Association between age-of-asthma onset and genotypes at individual locus; 699 
Part B) Median of age-of-asthma onset as a function of the number of individual’s risk allele 700 
burden; Part C) Median of age-of-asthma onset by quintile of genetic risk score. 701 
Figure 4. Map of 16q12 region (build 37.3 position: 50,723,355-50,860,722) and haplotype 702 
reconstruction for SNPs found associated with inflammatory bowel disease (among which 703 
Crohn’s disease, blue), leprosy (green) or asthma (red) or with the expression of CYLD or 704 
NOD2 (black). Linkage disequilibrium plot was obtained using Hapmap2 CEU reference 705 
sample from Haploview57 (values and colors reflect r² and D’ respectively). The 16q12 top 706 
SNP (rs1861760) associated with time-to-asthma onset is indicated in bold. 707 
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